Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years

← catalyst calendar

NCT06891417 · readout in 502 d

Sponsored by Sanofi (industry) · SNY — their whole pipeline →.

Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
1,560estimated
Sites
7
Country
Australia

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2025-03-27actualWhen the study began enrolling
Primary completion2028-01-03estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2028-01-03estimatedThe whole study's end, after follow-up
First posted2025-03-24actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-04-08actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Chlamydia Trachomatis Immunization

Interventions

  • Biological: Chlamydia mRNA Vaccine
  • Other: Placebo

Primary outcomes

what the primary-completion date above is the date OF
Presence of immediate unsolicited systemic adverse events (AEs)
measured Within 30 minutes after each vaccine injection
Presence of solicited injection site and systemic reactions
measured Up to 7 days after each vaccine injection
Presence of unsolicited AEs
measured Up to 28 days after each vaccine injection.
Presence of medically attended adverse events (MAAEs)
measured Up to 6 months after last vaccine injection
Presence of all serious AEs (SAEs) and all adverse events of special interest (AESIs)
measured Up to 12 months after last vaccine injections
Presence of related SAEs, and fatal SAEs
measured Throughout the study, appriximatley 18 months
Presence of out-of-range biological test results (Sentinel Cohort and Safety Subset of Main Cohort)
measured Up to 7 days after each vaccination injections

Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed